Jessica is a senior editor, contributing most frequently to daily pharmaceutical coverage in Scrip and Pink Sheet. With a lengthy career covering the pharmaceutical sector, she specializes primarily in business and commercial news, launch strategy, M&A and market access issues.
Latest from Jessica Merrill
CEO Christophe Bourdon talked to Scrip about the company’s revitalization as revenue grew 10% in the third quarter.
Pfizer continued its reign as the Scrip 100 leader for a third year, while Lilly and Novo climbed higher.
The Swiss pharma acquired Kate Therapeutics for up to $1.1bn, gaining preclinical gene therapies for neuromuscular conditions and novel platform technology.
Chris Boshoff has been with Pfizer more than 10 years and has led oncology R&D and the integration of Seagen. He will succeed Mikael Dolsten, who will depart after leading R&D for nearly 15 years.
The new formulation is expected to play a role in helping Merck maintain its multibillion-dollar cancer franchise after Keytruda loses exclusivity in 2028.
The company has reached agreement with the US FDA on a pivotal trial for RGX-202 through an accelerated pathway.